Viatris launches Ryzumvi for mydriasis reversal

Viatris is launching Ryzumvi, the first FDA-approved eyedrop for reversing dilation, with an onset of action in 30 minutes. The drug was approved based on positive results from two trials involving 553 patients aged 12 to 80 years. Patients who received two drops of Ryzumvi showed a significant improvement in pupil diameter compared to those who received a placebo. This new eyedrop offers a quick and effective solution for reversing dilation and is a significant advancement in eye care.

Source link

error: Content is protected !!